MindBio reports sustained antidepressant response with microdosed psychedelic

20 August 2024

Canada-headquartered psychedelic medicine company MindBio Therapeutics (CSE: MBIO) yesterday reported durability data from Phase IIa clinical trials in depressed patients testing MB22001, MindBio's proprietary self-administered take home microdose of lysergic acid diethylamide (LSD).

The company said it is pleased to report a significant and sustained antidepressant response in patient follow up three months post treatment. However, investors were not impressed, sending MindBio’s shares down 14.3% to C$0.03.

The Phase IIa clinical trial demonstrated excellent safety, adherence and tolerance profile in doses tested. This was consistent with the Phase I study results and the findings augment the mounting evidence that MB22001 is a safe and effective drug for treating depression with a psychedelic medicine to patients out in the community. The scientific manuscript has recently been submitted to the prestigious British Journal of Psychiatry for peer review and publishing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK